The Bio Report
Mapping Cellular Stress Biology to Tackle Undruggable Targets
Why It Matters
Understanding and targeting cellular stress pathways opens new therapeutic avenues for diseases that have eluded traditional target‑centric approaches, potentially accelerating the development of treatments for cancer, Parkinson's, obesity, and more. As the biotech industry seeks more efficient, capital‑light drug discovery models, Soleil's real‑time phenotypic AI platform offers a timely solution that could reshape how we tackle complex, unmet medical needs.
Key Takeaways
- •AI imaging maps cellular stress to discover undruggable targets.
- •Platform flips drug discovery: phenotype-first, disease later.
- •Two first‑in‑class small molecules advancing for AML and solid tumors.
- •Platform applies to neurodegeneration, obesity, hair loss, beyond oncology.
- •Real‑time trial data accelerates development and capital efficiency.
Pulse Analysis
Soleil Therapeutics leverages an AI‑driven imaging platform to quantify thousands of intracellular events, turning cellular stress responses into a discovery engine. By measuring how live cells adapt, recover, or die under drug exposure, the company builds a “Soleil map” that captures unique phenotypic signatures. This approach flips the conventional target‑first paradigm, allowing researchers to start with a drug‑induced phenotype and later match it to disease contexts, opening pathways to previously undruggable targets across oncology and beyond.
The platform has already yielded two first‑in‑class oral small molecules. SOL001, a stress‑inducing agent, shows potent preclinical activity against acute myeloid leukemia and broader liquid and solid tumors, with favorable tolerability and synergy with standard‑of‑care regimens. SOL002, a distinct scaffold, targets solid tumors such as head‑and‑neck squamous cell carcinoma. Both candidates are moving through IND‑enabling studies, with SOL001 slated for a Phase 1 trial by year‑end and SOL002 expected to follow, illustrating how phenotypic screening can compress timelines and improve capital efficiency.
Beyond cancer, Soleil’s stress‑biology platform is being applied to neurodegenerative disorders like Parkinson’s disease, metabolic conditions such as obesity, and even hair regeneration. Published pre‑clinical data in cardiovascular and stroke models validate the technology’s versatility. The company is actively seeking partnerships to co‑develop these pipelines, leveraging real‑time clinical trial analytics—an emerging FDA‑endorsed model—to further accelerate development and reduce the industry’s historically high failure rates.
Episode Description
Cells continuously sense their environment and in response to stressors, adapt, recover, or die. Soley Therapeutics uses its AI platform to capture thousands of intracellular features and map how cells sense, interpret, and respond to stress. The approach gives Soley the ability to pursue previously undruggable targets. It has generated more than 10 novel oncology programs in less than two years and advanced two first‑in‑class experimental small molecule therapies toward the clinic. Yerem Yeghiazarians, co-founder and CEO of Soley, discusses the science behind the company’s first-in-class lead candidate, the applicability of Soley’s platform to a broad set of diseases, and the capital efficiency of the company’s approach to drug development.
Comments
Want to join the conversation?
Loading comments...